Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116983 | PMC |
| http://dx.doi.org/10.1007/s00415-025-13108-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenomic analysis of low-density lipoprotein receptor 3' untranslated region genetic variants influencing rosuvastatin efficacy in Chinese dyslipidemia patients.
Pharmacogenet Genomics
September 2025
Department of Cardiology, Tengzhou Central People's Hospital, Tengzhou, Shandong.
Objectives: Dyslipidemia is a crucial risk factor for atherosclerotic cardiovascular disease. Although rosuvastatin is widely used, treatment response varies significantly due to genetic variation. This study investigated the pharmacogenomic impact of low-density lipoprotein receptor (LDLR) 3' untranslated region (UTR) variants on rosuvastatin efficacy in a Chinese Han adult cohort with dyslipidemia.
View Article and Find Full Text PDFCorrection: Nasal food challenge with hen's egg white allergen.
Allergy Asthma Clin Immunol
August 2025
Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Zwirki i Wigury 61 str, 02-097, Warsaw, Poland.
Pharmacogenetic study of antipsychotic-induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association Study.
Transl Psychiatry
August 2025
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Second-generation antipsychotics (SGAs) are widely used to treat schizophrenia (SCZ), but they often induce metabolic side effects like dyslipidemia and obesity. We conducted genome-wide association studies (GWASs) to identify genetic variants associated with SGA-induced lipid and BMI changes in Chinese SCZ patients. A longitudinal cohort of Chinese SCZ receiving SGAs was followed for up to 18.
View Article and Find Full Text PDFPublisher Correction: Cytoplasmic PXR regulates glucose metabolism by binding mRNAs and modulating their stability.
Nat Struct Mol Biol
August 2025
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
Pathway-Specific Polygenic Scores for Predicting Clinical Lithium Treatment Response in Patients With Bipolar Disorder.
Biol Psychiatry Glob Open Sci
September 2025
Discipline of Psychiatry, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Background: Polygenic scores (PGSs) hold the potential to identify patients who respond favorably to specific psychiatric treatments. However, their biological interpretation remains unclear. In this study, we developed pathway-specific PGSs (PS) for lithium response and assessed their association with clinical lithium response in patients with bipolar disorder.
View Article and Find Full Text PDF